Accountability through facts.
Federal · H.R. 5376 · 117th Congress
To provide for reconciliation pursuant to title II of S. Con. Res. 14
This bill imposes an alternative minimum tax of 15% of the average annual adjusted financial statement income of domestic corporations (excluding Subchapter S corporations, regulated investment companies, and real estate investment trusts) that exceeds $1 billion over a specified 3-year period. The tax is effective in taxable years beginning after December 31, 2022.
First two sentences of the Congressional Research Service's summary · Congress.gov ↗
This bill imposes an alternative minimum tax of 15% of the average annual adjusted financial statement income of domestic corporations (excluding Subchapter S corporations, regulated investment companies, and real estate investment trusts) that exceeds $1 billion over a specified 3-year period.
Passed the House and the Senate. No signing or veto is recorded yet.
Find your representatives to see how yours voted.
First two sentences of the Congressional Research Service's summary · Congress.gov ↗. A plain-words version comes later. Official page ↗
Your reps
Find your representatives to see how yours voted.
Latest final vote: Passed · U.S. House · Aug 12, 2022
Official record ↗Constitution
Not yet mapped. The parts of the Constitution this bill touches appear here once an analysis is written and checked.
Want an analysis of this bill? A full analysis maps every provision it touches.
All votes
U.S. House · Aug 12, 2022 · Final passage
On Motion to Concur in the Senate Amendment · Passed
Official record ↗By party
| Party | Yes | No | Present | Not voting |
|---|---|---|---|---|
| Republican | 0 | 152 | 0 | 1 |
| Democratic | 146 | 0 | 0 | 0 |
| Democrat | 11 | 0 | 0 | 0 |
By state (45)
| State | Yes | No | Present | Not voting |
|---|---|---|---|---|
| AL | 1 | 3 | 0 | 1 |
| AR | 0 | 4 | 0 | 0 |
| AZ | 2 | 3 | 0 | 0 |
| CA | 42 | 11 | 0 | 0 |
| CO | 3 | 1 | 0 | 0 |
| CT | 5 | 0 | 0 | 0 |
| DE | 1 | 0 | 0 | 0 |
| FL | 5 | 13 | 0 | 0 |
| GA | 4 | 5 | 0 | 0 |
| HI | 1 | 0 | 0 | 0 |
| IA | 0 | 3 | 0 | 0 |
| ID | 0 | 2 | 0 | 0 |
| IL | 10 | 3 | 0 | 0 |
| IN | 2 | 3 | 0 | 0 |
| KS | 1 | 2 | 0 | 0 |
| KY | 0 | 5 | 0 | 0 |
| LA | 1 | 4 | 0 | 0 |
| MA | 9 | 0 | 0 | 0 |
| MD | 3 | 1 | 0 | 0 |
| ME | 2 | 0 | 0 | 0 |
| MI | 4 | 5 | 0 | 0 |
| MN | 3 | 4 | 0 | 0 |
| MO | 1 | 3 | 0 | 0 |
| MS | 1 | 2 | 0 | 0 |
| NC | 2 | 5 | 0 | 0 |
| NE | 0 | 3 | 0 | 0 |
| NH | 1 | 0 | 0 | 0 |
| NJ | 5 | 2 | 0 | 0 |
| NM | 2 | 0 | 0 | 0 |
| NV | 3 | 1 | 0 | 0 |
| NY | 12 | 4 | 0 | 0 |
| OH | 3 | 7 | 0 | 0 |
| OK | 0 | 4 | 0 | 0 |
| OR | 1 | 1 | 0 | 0 |
| PA | 5 | 8 | 0 | 0 |
| SC | 1 | 4 | 0 | 0 |
| SD | 0 | 1 | 0 | 0 |
| TN | 1 | 6 | 0 | 0 |
| TX | 9 | 17 | 0 | 0 |
| UT | 0 | 3 | 0 | 0 |
| VA | 2 | 3 | 0 | 0 |
| VT | 1 | 0 | 0 | 0 |
| WA | 6 | 1 | 0 | 0 |
| WI | 2 | 4 | 0 | 0 |
| WV | 0 | 1 | 0 | 0 |
The breakdown counts the 310 members whose positions are loaded; the totals above are the official record's.
Party is as each member's record lists it. Counts are of recorded positions, nothing more.
Every member's vote
310 members, by last name.
From the official record of each vote. A member who left office keeps their recorded position; their page shows the years they served.
Money
Lobbying reports for this bill haven't been searched yet. They're searched for every bill in this Congress with a final-passage vote or committee action, newest first.
History
- Nov 19, 2021U.S. House: Table Motion to Reconsider · Passed ↗
- Nov 19, 2021U.S. House: On Passage · Passed ↗
- Nov 19, 2021U.S. House: On Motion to Recommit · Failed ↗
- Aug 6, 2022U.S. Senate: On the Motion to Proceed · Motion to Proceed Agreed to ↗
- Aug 7, 2022U.S. Senate: On Passage of the Bill · Bill Passed ↗
- Aug 7, 2022U.S. Senate: On the Motion · Motion Rejected ↗
- Aug 7, 2022U.S. Senate: On the Motion · Motion Rejected ↗
- Aug 7, 2022U.S. Senate: On the Motion · Motion Rejected ↗
- Aug 7, 2022U.S. Senate: On the Motion · Motion Rejected ↗
- Aug 7, 2022U.S. Senate: On the Motion · Motion Rejected ↗
- Aug 7, 2022U.S. Senate: On the Motion · Motion Rejected ↗
- Aug 7, 2022U.S. Senate: On the Motion · Motion Rejected ↗
- Aug 7, 2022U.S. Senate: On the Motion · Motion Rejected ↗
- Aug 7, 2022U.S. Senate: On the Motion · Motion Rejected ↗
- Aug 7, 2022U.S. Senate: On the Motion · Motion Rejected ↗
- Aug 12, 2022U.S. House: On Motion to Concur in the Senate Amendment · Passed ↗
Recorded votes on this bill, passage without a recorded vote, and the final action, as their sources record them. Committee and other steps without a recorded vote aren't listed; the official page has every action.
Final action
Not checked yet. The President's action on a bill appears here after the data sync looks it up.
From Congress.gov's record of the bill's actions.
Full text
Official summary (Congressional Research Service)
TITLE I--COMMITTEE ON FINANCE Subtitle A--Deficit Reduction Part 1--Corporate Tax Reform (Sec. 10101) This bill imposes an alternative minimum tax of 15% of the average annual adjusted financial statement income of domestic corporations (excluding Subchapter S corporations, regulated investment companies, and real estate investment trusts) that exceeds $1 billion over a specified 3-year period. The tax is effective in taxable years beginning after December 31, 2022. Part 2--Excise Tax on Repurchase of Corporate Stock (Sec. 10201) The bill imposes a non-deductible 1% excise tax on the fair market value of stock repurchased by a publicly traded domestic corporation after 2022, with certain exceptions, including for repurchases that are part of a reorganization, are less than $1 million, that are contributed to certain tax-exempt retirement plans, or that are treated as a dividend. The tax applies to purchases of corporate stock by certain corporate subsidiaries and foreign corporations. Part 3--Funding the Internal Revenue Service and Improving Taxpayer Compliance (Sec. 10301) The bill provides additional funding for the Internal Revenue Service for taxpayer services and enforcement, including for operations support, business systems modernization, and the development of a free direct e-file tax return system. It also provides additional funding for the Department of the Treasury Inspector General for Tax Administration, the Office of Tax Policy, the Tax Court, and Treasury departmental offices. Subtitle B--Prescription Drug Pricing Reform Part 1--Lowering Prices Through Drug Price Negotiation (Sec. 11001) The bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Specifically, the CMS must negotiate maximum prices for brand-name drugs that do not have other generic equivalents and that account for the greatest Medicare spending. The CMS must negotiate the prices of 10 drugs that are covered under the Medicare prescription drug benefit in 2026, 15 drugs that are covered under the Medicare prescription drug benefit in 2027, 15 drugs that are covered under the Medicare prescription drug benefit or under Medicare medical services in 2028, and 20 drugs that are covered under the Medicare prescription drug benefit or under Medicare medical services in 2029 and each year thereafter. The selected drugs must be among the 50 drugs with the highest total spending over the most recent 12-month period under the Medicare prescription drug benefit or Medicare medical services and must have had market approval for at least 7 years (for drug products) or 11 years (for biologics). The bill excludes (1) orphan drugs that are approved to treat only one rare disease or condition, (2) plasma-derived products, and (3) drugs that account for less than $200 million in annual Medicare spending (adjusted annually for inflation). The CMS must enter into agreements with drug manufacturers to negotiate prices; manufacturers must submit information relating to costs and other data as part of the negotiation process. Manufacturers that fail to comply with negotiation requirements are subject to civil penalties. (Sec. 11002) The CMS may delay negotiations for certain biologics with pending biosimilars for up to two years upon manufacturer request. (Sec. 11003) Drug manufacturers are subject to excise taxes for failing to comply with negotiation requirements, such as failing to furnish required information during the negotiation process or failing to reach an agreement by the required deadline. The tax does not apply if manufacturers withdraw their drugs from Medicare and Medicaid coverage. (Sec. 11004) The bill provides funds for FY2022 for the CMS to implement this program. Part 2--Prescription Drug Inflation Rebates (Sec. 11101) In addition, the bill requires drug manufacturers to issue rebates to the CMS for brand-name drugs without generic equivalents under Medicare medical services that cost $100 or more per year per individual and for which prices increase faster than inflation. Manufacturers that fail to comply are subject to civil penalties. The bill provides funds through FY2031 for the CMS to implement this rebate program. (Sec. 11102) The bill similarly requires drug manufacturers to issue rebates to the CMS for brand-name drugs without generic equivalents under the Medicare prescription drug benefit that cost $100 or more per year per individual and for which prices increase faster than inflation. Manufacturers that fail to comply are subject to civil penalties. The bill provides funds through FY2031 for the CMS to implement this rebate program. Part 3--Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries (Sec. 11201) The bill eliminates beneficiary cost-sharing above the annual out-of-pocket spending threshold under the Medicare prescription drug benefit beginning in 2024 and caps annual out-of-pocket spending at $2,000 in 2025 (with annual adjustments thereafter). It also establishes a program under which drug manufacturers provide discounts to beneficiaries who have incurred costs above the annual deductible beginning in 2025. The bill also limits base premiums under the Medicare prescription drug benefit for 2024 through 2030 to a 6% annual increase or the amount that would otherwise apply under the prior methodology, whichever is less. The bill provides funds through FY2031 for the CMS to implement these changes and requirements. (Sec. 11202) The bill also establishes a process through which beneficiaries, including those eligible for low-income subsidies, may have their monthly out-of-pocket costs capped and paid in monthly installments beginning in 2025; it provides funds for FY2023 for the CMS to implement this process. Part 4--Continued Delay of Implementation of Prescription Drug Rebate Rule (Sec. 11301) The bill further delays until 2032 implementation of a Department of Health
Source ↗